Kilitch Drugs (India) Limited

Kilitch Drugs (India) Limited

Aktie · INE729D01010 (XBOM)
Übersicht
AI-gestützte Analyse
Fundamental-Analyse
Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu Kilitch Drugs (India) Limited
Kein Kurs
Schlusskurs XBOM 29.04.2026: 152,75 INR
29.04.2026 09:59
Aktuelle Kurse von Kilitch Drugs (India) Limited
BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNSE: NSE
NSE
KILITCH.NS
INR
29.04.2026 09:59
154,11 INR
0,33 INR
+0,21 %
XBOM: MSE
MSE
KILITCH.BO
INR
29.04.2026 09:46
152,75 INR
-1,03 INR
-0,67 %
Free Float & Liquidität
Free Float 21,19 %
Shares Float 7,41 M
Ausstehende Aktien 34,96 M
Firmenprofil zu Kilitch Drugs (India) Limited Aktie
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of liquid ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrup, gripe water, and oral powder and liquid in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Unternehmensdaten

Name Kilitch Drugs (India) Limited
Firma Kilitch Drugs (India) Limited
Website https://www.kilitch.com
Heimatbörse XBOM MSE
ISIN INE729D01010
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Mukund Prataprai Mehta
Marktkapitalisierung 5 Mrd.
Land Indien
Währung INR
Mitarbeiter 0,2 T
Adresse 37/39, Ujagar Industrial Estate, 400088 Mumbai
IPO Datum 2002-03-05
Dividenden von 'Kilitch Drugs (India) Limited'
Ex-Datum Dividende pro Aktie
20.09.2019 0,50 INR
18.09.2018 0,50 INR
24.09.2012 30,00 INR
24.09.2012 30,00 INR
18.08.2011 1,00 INR
18.08.2011 1,00 INR
14.10.2010 1,00 INR
10.09.2009 1,00 INR
10.09.2008 1,00 INR
15.11.2007 1,00 INR

Aktien-Splits

Datum Split
24.03.2026 2:1
15.07.2025 1021:1000

Ticker Symbole

Name Symbol
MSE KILITCH.BO
NSE KILITCH.NS
Weitere Aktien
Investoren, die Kilitch Drugs (India) Limited halten, haben auch folgende Aktien im Depot:
ISHS2MEQDADV EOA
ISHS2MEQDADV EOA ETF
TRANSCDA TRUST 17/77 FLR
TRANSCDA TRUST 17/77 FLR Anleihe